Weekender 11/20/15

New Jersey is at the top of the list for biotech growth potential, Camden ‘Eds and Meds’ have a $2 billion impact, Chugai opens new US facility in the Garden State, new FDA drug and medical device approvals and more. New Jersey’s innovative life sciences ecosystem keeps it coming…

New Jersey’s dominance in biotechnology was validated with a top ranking nationally in the Biotech Growth Potential category in Business Facilities Magazine‘s Annual Rankings Report, as a result of New Jersey’s ability to attract new players and grant funding, leverage its world-class research hubs, support startups and develop new industry clusters.

A task force comprised of Camden’s higher education and health care leaders released a new report indicating that its nine anchor institutions have had an economic impact of more than $2 billion on the city, while creating more than 2,300 new jobs.

Congratulations to BioNJ Member Chugai Pharma USA Inc., the American arm of Japanese drugmaker Chugai Pharmaceutical Co. Ltd., on the opening of its new U.S. office in Berkeley Heights, New Jersey. The office will be used for translational clinical research.

BioNJ Members Genmab and Johnson & Johnson announced FDA approval of DARZALEX™ (daratumumab) injection for intravenous infusion for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy. This indication was approved under accelerated approval based on response rate.

Parsippany-based Medtronic received FDA approval for its MyCareLink Smart Monitor, the first app-based remote monitoring for implantable pacemakers. In September, Medtronic also nabbed FDA approval for and launched its MiniMed Connect, which links that insulin pump/continous glucose monitor to an app for remote monitoring and messaging.

The FDA has accepted for filing and priority review a supplemental Biologics License Application from BioNJ Member Bristol-Myers Squibb for Opdivo for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. The FDA previously granted Opdivo Breakthrough Therapy Designation for this indication, underscoring the critical need for new treatment options for patients with advanced RCC who have received prior therapy. Because Patients Can’t WaitSM.

Congratulations to John Kouten, President and CEO of BioNJ Member JFK Communications, for getting New Jersey’s story told in NJBIZ. He shared the three key reasons why the future is bright for the Garden State’s life sciences ecosystem: Talent, Unparalleled Support and Location…Location…Location! Click here for the full story.

Excitement is building for BioNJ’s first-ever Inspiring Women in STEM Conference, taking place December 4. The room is near capacity. So, register now.

Click here to read this week’s Weekender.